![]() ![]() Tablo is a registered trademark of Outset Medical, Inc. Outset Medical reimagined hemodialysis with Tablo, an all-in-one device that purifies water and produces dialysate on-demand, making it easier for patients. Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. ![]() The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. ![]() Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. View Outset Medical (location in California, United States, revenue, industry and description. Use the PitchBook Platform to explore the full. Cooley LLP acted as legal advisor for Outset Medical in connection with the financing. Information on stock, financials, earnings, subsidiaries, investors, and executives for Outset Medical. Department of Health and Human Services (HHS) awarded a contract for the use of Tablo in communities hit by natural disasters. Medical Assistant II-Rheumatology (Lemoyne) Job ID: 053272287 Status: Full-Time. have adopted Tablo for hospital and clinic dialysis, and the U.S. Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. Leading health systems and medical centers across the U.S. Being able to work with an experienced technological partner from the outset is definitely a gamechanger for a Medtech novice, especially in the realm of. ( OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the 20 th Annual Morgan Stanley Global Healthcare Conference on Tuesday, Septemat 11:55am PT / 2:55pm ET.Ī live and archived webcast of the fireside chat will be available on the “Investors” section of the Outset website at. The WSGR team that represented Outset Medical in the transaction included partner Philip Oettinger and associates Brian Appel and Drew Morris.įor more information, please see the company's press release.Outset Medical, Inc. ![]() In addition to its acute and chronic care commercial expansion, the company is conducting a clinical trial to expand Tablo's labeled indication to include home use. Designed to reduce the cost and complexity of dialysis, Tablo expands how, when, and where dialysis can be provided. Rowe Price Associates, and Warburg Pincus.Īccording to a company press release, Outset Medical will use the proceeds from the financing to increase production capabilities and accelerate commercial expansion of its Tablo® Hemodialysis System in acute and chronic care markets in the U.S. The round was led by new investor Mubadala Investment Company, Abu Dhabi's leading investment company, with participation from existing investors Baxter Ventures, the venture capital arm of Baxter International, Fidelity Management and Research Company, Partner Fund Management, Perceptive Advisors, funds advised by T. Wilson Sonsini Goodrich & Rosati represented Outset Medical in the transaction. On August 28, 2018, Outset Medical, a Silicon Valley-based commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, announced that it has raised $132 million in a Series D round of equity financing. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |